APx Acquisition Corp. I (APXI)
| Previous close | 11.11 |
| Open | 11.11 |
| Bid | 11.11 x 1200 |
| Ask | 11.20 x 1300 |
| Day's range | 11.11 - 11.11 |
| 52-week range | 9.86 - 11.11 |
| Volume | |
| Avg. volume | 7,389 |
| Market cap | 120.756M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 79.36 |
| EPS (TTM) | 0.14 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company
APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and pr
Simply Wall St.APx Acquisition Corp. I (NASDAQ:APXI) most popular amongst private companies who own 39% of the shares, institutions hold 38%
Key Insights Significant control over APx Acquisition I by private companies implies that the general public has more...
- Business Wire
APx Acquisition Corp. I Announces Approval of Extension Meeting Proposals and Intention to Extend Combination Period
NEW YORK, February 27, 2023--APx Acquisition Corp. I ("APx" or the "Company"), a special purpose acquisition company, announced today that at the extraordinary general shareholders meeting held on February 27, 2023, the Company’s shareholders voted in favor of proposals to approve an amendment to the Investment Management Trust Agreement, dated December 6, 2021, and the Company’s Amended and Restated Memorandum and Articles of Association (the "Amended Articles of Association") to change the pay
